[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) Form 144 notice reports a proposed sale of 19,658 shares of common stock to be executed through Stifel Nicolaus on 09/03/2025 with an aggregate market value of $1,195,421.00. The shares represent part of an award acquired on 01/02/2019 by option exercise; the planned proceeds will be received in cash.

The filing lists total outstanding shares of 159,391,229 for the issuer and discloses recent sales by the same person on 08/04/2025 of 7,095 and 2,454 shares generating gross proceeds of $303,074.00 and $105,627.00 respectively. The filer affirms no undisclosed material adverse information and provides a broker name and address for execution.

Positive

• Complete disclosure of planned sale details including shares (19,658), aggregate value ($1,195,421.00), broker (Stifel Nicolaus), and sale date (09/03/2025).
• Acquisition method stated (option exercise on 01/02/2019) and payment method for sale proceeds (cash) are explicitly provided.
• Recent sales by the same person on 08/04/2025 are reported with amounts and gross proceeds, enhancing transparency.

Negative

• Insider selling activity: the filer disposed of 9,549 shares on 08/04/2025, which may be viewed negatively by some investors as increased insider liquidity.
• No information is provided about the filer’s relationship to the issuer or holdings beyond the disclosed transactions, limiting context for the sales.

Insights

Securities Analyst

TL;DR Routine insider sale notice: specific shares, acquisition method, broker, and recent August dispositions are disclosed.

The Form 144 is a standard regulatory notice identifying a planned sale of 19,658 shares via Stifel Nicolaus on 09/03/2025 and confirms the shares were acquired by option exercise on 01/02/2019. Recent reported August 4, 2025 sales totaling 9,549 shares with stated gross proceeds are included, which provides transparency on recent insider liquidity. No financial performance metrics or issuer-specific qualitative disclosures are contained in the filing, limiting analysis to transaction and procedural details.

Corporate Governance Expert

TL;DR Filing meets disclosure requirements but contains no governance changes or material issuer updates.

The notice supplies required elements: identity of broker, exact share counts, acquisition date and method, planned sale date, and a representation regarding material nonpublic information. There is no indication of a new trading plan date or 10b5-1 adoption noted. From a governance perspective the document is a compliance disclosure rather than an event that alters corporate control or board composition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	19658	1195421.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/02/2019	Option Exercise	Issuer			19658	09/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eugene Schneider 2855 Gazelle Ct Carlsbad MO 92010	Common Stock	08/04/2025	7095	303074.00
Eugene Schneider 2855 Gazelle Ct Carlsbad MO 92010	Common Stock	08/04/2025	2454	105627.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' (IONS) Form 144 report?

The Form 144 reports a proposed sale of 19,658 common shares to be sold via Stifel Nicolaus on 09/03/2025 with an aggregate market value of $1,195,421.00.

When and how were the shares being sold acquired?

The shares were acquired by option exercise on 01/02/2019 and the planned sale proceeds are to be received in cash.

Did the filer sell any Ionis shares recently?

Yes. The filing discloses two sales on 08/04/2025 of 7,095 and 2,454 shares, with gross proceeds of $303,074.00 and $105,627.00 respectively.

How many Ionis shares are outstanding according to the filing?

The filing states 159,391,229 shares outstanding for the issuer.

Which broker will execute the planned sale for IONS?

The listed broker is Stifel Nicolaus & Company Inc., 501 N Broadway, St. Louis, MO 63102.